AMNEAL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.66 USD | +2.94% |
|
-1.48% | +9.72% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to Amneal's First Quarter 2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Companyâs Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segmentâs portfolio includes central nervous system disorders (Parkinsonâs disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Companyâs AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
6.66
USD
Average target price
8.25
USD
Spread / Average Target
+23.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.72% | 2.06B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Transcript : Amneal Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022